Intech Investment Management LLC Has $802,000 Holdings in Insulet Co. (NASDAQ:PODD)

Intech Investment Management LLC boosted its position in shares of Insulet Co. (NASDAQ:PODD) by 219.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,073 shares of the medical instruments supplier’s stock after buying an additional 2,111 shares during the period. Intech Investment Management LLC’s holdings in Insulet were worth $802,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of PODD. Integrated Wealth Concepts LLC boosted its position in shares of Insulet by 1.7% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock worth $596,000 after acquiring an additional 42 shares in the last quarter. Horizon Investments LLC lifted its stake in Insulet by 3.1% during the fourth quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier’s stock worth $362,000 after purchasing an additional 42 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Insulet by 1.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock valued at $1,146,000 after purchasing an additional 43 shares in the last quarter. Glenmede Trust Co. NA increased its stake in shares of Insulet by 2.3% in the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock valued at $484,000 after purchasing an additional 47 shares during the last quarter. Finally, Graypoint LLC raised its holdings in shares of Insulet by 5.3% during the 4th quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock worth $243,000 after buying an additional 47 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on PODD. Stifel Nicolaus lifted their target price on Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research report on Friday, February 21st. Citigroup lifted their price target on shares of Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a report on Friday, February 21st. StockNews.com downgraded shares of Insulet from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th. Raymond James reaffirmed an “outperform” rating and set a $328.00 target price (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. Finally, Piper Sandler increased their price target on Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus target price of $292.06.

Insiders Place Their Bets

In related news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.47% of the company’s stock.

Insulet Stock Performance

NASDAQ:PODD opened at $268.32 on Monday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The company has a 50 day simple moving average of $272.04 and a two-hundred day simple moving average of $257.37. The company has a market capitalization of $18.84 billion, a PE ratio of 46.34, a P/E/G ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million during the quarter, compared to analysts’ expectations of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Research analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.